Biopharmaceutical company KalVista Pharmaceuticals Inc (Nasdaq: KALV) announced on Monday that it has received U.S. Food and Drug Administration (FDA) approval for EKTERLY (sebetralstat), the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in patients aged 12 and older.
EKTERLY is the first new on-demand therapy for HAE approved in over a decade, offering a transformative alternative to intravenous or subcutaneous options. Approval was based on the phase 3 KONFIDENT trial, the largest HAE trial to date, which demonstrated rapid symptom relief, attack resolution, and a safety profile comparable to placebo. Real-world data from the open-label KONFIDENT-S extension trial showed a median treatment initiation time of 10 minutes and symptom relief within 1.3 hours for severe attacks.
KalVista is launching EKTERLY immediately in the US, supported by the KalVista Cares patient access program. The company also has multiple regulatory applications under review internationally and is conducting additional trials in children aged two to 11.
Hereditary angioedema is a rare genetic condition marked by unpredictable and potentially life-threatening tissue swelling. EKTERLY's approval addresses a longstanding unmet need for a convenient, fast-acting, oral treatment option.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval